Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Phase II Study of Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer (The TELESCOPE Study)

NCT06604858 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT06604858
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06604858 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Phase II Study of Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer (The TELESCOPE Study)
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Completed
Start date
May 29, 2025
Completion date
July 7, 2026
Enrollment
31 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, triple negative breast cancer